Floatz logo

Monovalent [B.1.351] Cov2 Pres Dtm-As03

Rheumatoid Arthritis (RA)

National Institute of Allergy and Infectious Diseases (NIAID)vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Rheumatoid Arthritis (RA) cohort.

Asset / SponsorPhaseRating
Naltrexone
Truway Health, Inc.
Phase 4BBB
METHOTREXATE
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3BB
IBUPROFEN
Amgen
Phase 3BB
Tocilizumab
Hoffmann-La Roche
Phase 3BB
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BB

View all 38 →

Same molecule, other indications

Monovalent [B.1.351] Cov2 Pres Dtm-As03 is also rated in:

pemphigus vulgarisDormant
CCC
Indicative ·
53 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative ·
53 / 100
View asset →
systemic lupus erythematosusDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →